We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

61 hedge funds and large institutions have $379M invested in Foghorn Therapeutics in 2022 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 17 increasing their positions, 22 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more funds holding

Funds holding: 60 → 61 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

5.18% less ownership

Funds ownership: 65.31% → 60.13% (-5.2%)

23% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 22

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

31% less capital invested

Capital invested by funds: $553M → $379M (-$174M)

98% less call options, than puts

Call options by funds: $3K | Put options by funds: $196K

Holders
61
Holders Change
+1
Holders Change %
+1.67%
% of All Funds
0.96%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
12
Increased
17
Reduced
22
Closed
11
Calls
$3K
Puts
$196K
Net Calls
-$193K
Net Calls Change
+$2.38M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.76M
2
Morgan Stanley
Morgan Stanley
New York
+$6.54M
3
DM
Deerfield Management
New York
+$3.28M
4
DCM
Driehaus Capital Management
Illinois
+$3.16M
5
N
Nuveen
North Carolina
+$904K

Top Sellers

1
MIM
Monashee Investment Management
Massachusetts
-$5.49M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$5.19M
3
EI
EAM Investors
California
-$3.41M
4
EGI
EAM Global Investors
California
-$2.36M
5
PPA
Parametric Portfolio Associates
Washington
-$1.43M
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$193M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$48.7M +$9.76M +711,032 +29%
AG
3
Artal Group
Luxembourg
$26.2M – – –
EC
4
Euclidean Capital
New York
$19.2M – – –
BlackRock
5
BlackRock
New York
$17M -$430K -31,339 -3%
Morgan Stanley
6
Morgan Stanley
New York
$15.7M +$6.54M +476,821 +86%
Vanguard Group
7
Vanguard Group
Pennsylvania
$13.1M +$221K +16,079 +2%
AI
8
Alphabet Inc
California
$7.63M – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$5.33M +$38.3K +2,789 +0.8%
DCM
10
Driehaus Capital Management
Illinois
$4.87M +$3.16M +230,000 +256%
State Street
11
State Street
Massachusetts
$4.85M +$215K +15,651 +5%
BC
12
Birchview Capital
Vermont
$4.48M -$274K -20,000 -6%
DM
13
Deerfield Management
New York
$3.64M +$3.28M +238,865 New
Northern Trust
14
Northern Trust
Illinois
$2.57M -$27.6K -2,014 -1%
Millennium Management
15
Millennium Management
New York
$2.47M +$345K +25,144 +18%
N
16
Nuveen
North Carolina
$1.52M +$904K +65,887 +140%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$931K -$553K -40,326 -40%
Citadel Advisors
18
Citadel Advisors
Florida
$892K +$803K +58,546 New
KCM
19
Kingdon Capital Management
New York
$826K -$1.37K -100 -0.2%
Charles Schwab
20
Charles Schwab
California
$790K +$14.5K +1,059 +2%
BBA
21
Baker Bros. Advisors
New York
$686K – – –
RJA
22
Raymond James & Associates
Florida
$398K +$181K +13,200 +102%
State of Wisconsin Investment Board
23
State of Wisconsin Investment Board
Wisconsin
$396K – – –
JGC
24
J. Goldman & Co
New York
$388K +$92.6K +6,750 +36%
RhumbLine Advisers
25
RhumbLine Advisers
Massachusetts
$345K +$44.2K +3,223 +17%
1
2 3

FHTX Hedge Fund Activity: Q1 2022 in Review

61 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q1 2022, worth a combined $379M — down 31% from $553M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new FHTX positions and 11 closed out — a net gain of 1 holder — while 17 added to existing stakes and 22 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $9.76M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $5.49M sold.

  • 61 institutional investors held Foghorn Therapeutics (FHTX) as of Q1 2022, up from 60 in Q4 2021.
  • Funds reported $379M of Foghorn Therapeutics stock for Q1 2022, down 31% quarter-over-quarter.
  • 12 funds opened new Foghorn Therapeutics positions in Q1 2022 and 11 closed out, a net change of +1 holder.
  • The largest Foghorn Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $9.76M added.
  • The largest Foghorn Therapeutics seller in Q1 2022 was Monashee Investment Management, an estimated $5.49M sold.

Based on aggregated 13F filings for Q1 2022.